The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
Ben StaalYing LiuDaniel BarnettPeter HsuehZonglin HeChongFeng GaoKatie PartykaMark W HurdAatur D SinghiRichard R DrakeYing HuangAnirban MaitraRandall E BrandBrian B HaabPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
sTRA is a validated serological biomarker of PDAC that yields improved performance over CA19-9. The new panels may enable surveillance for PDAC among people with elevated risk, or improved differential diagnosis among patients with suspected pancreatic cancer.